Aspirin for Prevention of Preeclampsia

• Status: Unknown status
• Trial end date: 2021-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

Prophylaxis with low-dose aspirin has been recommended to prevent preeclampsia, the rationale being that hypertension and abnormalities of coagulation in this disease are caused in part by an imbalance between vasodilating and vasoconstricting prostaglandins. Low-dose aspirin therapy inhibits thromboxane production more than prostacyclin production and therefore should protect against vasoconstriction and pathologic blood coagulation in the placenta. Initially, several single-center trials, mostly among women at increased risk for preeclampsia, demonstrated a substantial reduction in the risk of proteinuric hypertension as well as reductions in the incidences of preterm birth, infants small for gestational age, and perinatal death,

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aswan University Hospital
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Pregnant women presenting prior to 17+0 weeks' gestation.

• Moderate to high risk of preeclampsia.

• One or more of the following: previous history of preeclampsia, antiphospholipid antibodies, pre-existing diabetes, pre-existing hypertension, pre-existing renal disease, autoimmune disease, nulliparity, family history of preeclampsia, elevated BMI > 25, and maternal age <20 or >35.

• Give written informed consent.

Exclusion Criteria:

• Multiple gestations,

• fetal aneuploidy

• major fetal structural anomaly

• bleeding disorder

• allergy to aspirin

• women already on aspirin or heparin.